Home
/
Conditions
/ Inflammatory Gut Conditions
Gut Health
Schedule a Consultation
Inflammatory Gut Conditions
Inflammatory gut conditions represent a spectrum of diagnoses, from IBS and SIBO to inflammatory bowel disease, that share common upstream drivers while requiring condition-specific treatment approaches. What connects them is the convergence of gut microbiome imbalance, intestinal barrier dysfunction, immune dysregulation, and nervous system changes that produce inflammation at the gut mucosa level and beyond.
Gut HealthInflammatoryManageable
Spectrumfrom functional IBS to structural IBD, all share modifiable upstream drivers
Microbiomedysbiosis, barrier dysfunction, and immune dysregulation are the common mechanisms
Gut-Directedanti-inflammatory protocols produce meaningful outcomes across the spectrum
← Back to Conditions
Category: Gut Health | Also addressed: Gut Inflammation, Intestinal Inflammatory Disease, Mucosal Inflammation
What Is Inflammatory Gut Conditions?
Inflammatory gut conditions encompass the spectrum of intestinal mucosal inflammation from the mild but clinically consequential, including subclinical gut inflammation detectable on fecal calprotectin and GI-MAP without meeting criteria for inflammatory bowel disease, to the established IBDs of Crohn disease and ulcerative colitis. Functional medicine is most impactful in the subclinical inflammatory range and as a complementary layer for IBD patients who want to reduce inflammatory burden and medication dependence through root-cause treatment alongside conventional management.
Key principle: Gut inflammation is a consequence, not a complete diagnosis. Calprotectin elevation tells you that inflammation is present in the mucosal tissue. It does not tell you what is driving it. The driver may be dysbiosis, dietary antigens, intestinal permeability, mast cell activation, an infectious pathogen, or autoimmune mucosal attack. Identifying and treating the driver produces the resolution that anti-inflammatory management alone cannot sustain.
Why It Matters
Gut inflammation drives consequences far beyond the intestinal tract. Even modest mucosal inflammation produces intestinal permeability that allows LPS, dietary antigens, and bacterial fragments into systemic circulation, driving systemic inflammation, autoimmune activation, and neuroinflammation that operate independently of any gut symptoms the patient is aware of.
Why Root-Cause Evaluation Changes Outcomes
- Gut inflammation is bidirectionally linked to every major chronic disease category: metabolic syndrome, cardiovascular disease, autoimmune conditions, depression, and neurodegenerative disease all have demonstrable gut inflammatory and microbiome components not addressed by organ-specific treatments
- IBD is incompletely managed by conventional treatment alone: biologic medications suppress mucosal immune attack but do not address the microbiome dysbiosis, nutritional deficiencies, or environmental triggers sustaining disease activity; functional medicine provides the complementary root-cause treatment layer
- Fecal calprotectin is underused as a screening tool: it is inexpensive, non-invasive, and distinguishes structural mucosal inflammation from functional IBS; it is not routine in patients with chronic gut symptoms before colonoscopy is scheduled
- Vitamin D deficiency in IBD has direct mucosal consequences: vitamin D receptor signaling on intestinal epithelial cells is required for antimicrobial peptide production and regulatory T-cell induction that maintain mucosal immune homeostasis
The Microbiome-Inflammation Connection
- Faecalibacterium prausnitzii is the most important anti-inflammatory species: producing butyrate as the primary colonocyte fuel and a potent NF-kB inhibitor; its depletion is the most consistent microbiome finding in IBD and removes the most important endogenous intestinal anti-inflammatory brake available
- Dysbiosis sustains inflammation, not just reflects it: elevated E. coli, Fusobacterium, and Ruminococcus gnavus actively drive the inflammatory signaling that conventional immunosuppression reduces but cannot eliminate while dysbiosis continues
- Gut-brain axis amplification: gut inflammation drives neuroinflammation through vagal nerve signaling and cytokine translocation; the fatigue, brain fog, and mood symptoms of IBD are direct neurological consequences of gut inflammatory burden
- SIBO complicates IBD in a large proportion of patients: particularly post-surgical IBD patients and those on chronic acid-suppressing medications; SIBO adds a fermentative symptom burden that biologic therapy alone cannot address
Common Symptoms
Symptoms of inflammatory gut conditions range from the obvious to the subtle and systemic. The extra-intestinal manifestations of IBD in particular are frequently managed as independent conditions without connection to the gut inflammatory driver.
Primary Intestinal Symptoms
- Abdominal pain and cramping, often related to bowel movements
- Diarrhea, watery or bloody depending on location and severity
- Urgency and frequency of bowel movements
- Rectal bleeding in ulcerative colitis and distal Crohn disease
- Bloating and distension from dysbiosis and inflammation disrupting motility
Systemic Consequences
- Fatigue disproportionate to gut symptoms from systemic cytokine burden and malabsorption
- Unintentional weight loss or difficulty maintaining weight from malabsorption
- Nutritional deficiencies: B12, vitamin D, iron, zinc, and folate from impaired absorption
- Anemia from iron deficiency through blood loss and malabsorption
- Growth impairment in pediatric onset IBD from sustained nutritional insufficiency
Extra-Intestinal Manifestations
- Joint pain and arthritis from enteropathic arthritis driven by gut-immune axis
- Skin manifestations including erythema nodosum and pyoderma gangrenosum
- Eye involvement including uveitis and episcleritis
- Brain fog and mood symptoms from gut-brain axis neuroinflammatory signaling
- Elevated inflammatory markers including fecal calprotectin and hs-CRP
Root Causes: A Functional Medicine Perspective
Identifying the specific drivers of mucosal inflammation guides both the conventional and functional medicine treatment decisions. The driver determines which intervention has the most mechanistic impact.
Gut Microbiome Dysbiosis as the Primary Driver
The characteristic IBD microbiome pattern, including reduced Faecalibacterium prausnitzii, Akkermansia muciniphila, and Bifidobacterium alongside elevated E. coli, Fusobacterium, and Ruminococcus gnavus, is not simply a consequence of intestinal inflammation but is also a driver of it. F. prausnitzii is the most important single anti-inflammatory species in the gut, producing butyrate and the anti-inflammatory protein MAM. Its depletion removes the most important endogenous intestinal anti-inflammatory brake available. Restoring F. prausnitzii through high-fiber prebiotic nutrition and targeted probiotic support is the most consistently beneficial microbiome intervention for intestinal inflammatory conditions.
Dietary Antigens and Intestinal Permeability
Gliadin peptides from gluten directly increase intestinal permeability through zonulin upregulation, activating innate immune responses in the intestinal epithelium. This mechanism operates in susceptible individuals without celiac disease and is relevant to all IBD patients. Food sensitivity IgG panels and elimination protocols identify additional dietary antigens sustaining mucosal immune activation. Specific carbohydrate diet, low-FODMAP during flares, and the IBD anti-inflammatory diet all have clinical evidence for symptom reduction. Intestinal permeability measured by zonulin perpetuates the immune-antigen contact driving autoimmune mucosal attack in a self-amplifying cycle requiring direct barrier repair to interrupt.
HPA Axis and Stress as a Flare Trigger
CRH receptors are distributed throughout the gut wall. Psychological and physiological stress activates these receptors directly, increasing intestinal permeability, stimulating mast cell degranulation, and altering mucosal immune activation independently of the systemic HPA response. This is the mechanism by which stress reliably triggers IBD flares. HPA axis assessment and stress physiology management are mechanistically relevant components of inflammatory gut treatment. Psychological stress management including CBT and mindfulness-based stress reduction has demonstrated reductions in IBD flare frequency in controlled trials.
Vitamin D Deficiency and Mucosal Immune Dysregulation
Vitamin D receptor signaling on intestinal epithelial cells directly regulates antimicrobial peptide production, tight junction protein expression, and regulatory T-cell induction in the mucosal immune tissue. Vitamin D deficiency, nearly universal in IBD patients, removes these mucosal immune regulatory functions simultaneously and is a direct driver of the mucosal vulnerability that allows dysbiosis-driven inflammation to establish and persist. Optimizing vitamin D to 60 to 80 ng/mL is one of the highest-priority interventions in inflammatory gut management.
Conventional vs Functional Medicine Approach
Conventional gastroenterology manages established IBD with 5-ASA compounds for UC, immunomodulators including azathioprine and 6-MP, and biologics targeting TNF-alpha, IL-12/23, and integrin trafficking. These are effective for inducing and maintaining remission and are appropriate and necessary for moderate-to-severe IBD. What they do not address is the microbiome dysbiosis sustaining disease activity, the nutritional deficiencies produced by intestinal malabsorption and inflammation, the dietary antigens driving mucosal immune activation, or the intestinal permeability perpetuating the immune-antigen contact that biologics cannot reach. Functional medicine adds these layers as complementary treatment alongside conventional management.
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Assessment tools | Colonoscopy with biopsy, fecal calprotectin, CRP, disease activity indices | GI-MAP stool analysis for microbiome characterization, zonulin for permeability, vitamin D targeting 60 to 80 ng/mL, comprehensive nutritional panel, dietary antigen evaluation |
| Fecal calprotectin use | Used for IBD monitoring; not routinely ordered before colonoscopy for IBS-like presentations | First-line non-invasive tool for distinguishing structural mucosal inflammation from functional gut disorders before endoscopy is scheduled |
| Microbiome | Not assessed or addressed in conventional IBD management | GI-MAP quantifies F. prausnitzii, Akkermansia, pathogen burden, and SCFA producers; targeted restoration is a primary intervention |
| Nutritional assessment | Weight monitoring, occasional B12 check in Crohn disease | Comprehensive panel: B12/MMA, vitamin D, iron/ferritin, zinc, folate, and omega-3 index at every clinical interval |
| Dietary intervention | Low-residue diet during flares; no systematic antigen evaluation | Gluten evaluation in all IBD patients; specific carbohydrate diet or IBD-AID for maintenance; food sensitivity panel for individual antigen identification |
Key Labs to Evaluate
A complete evaluation requires markers that characterize both the condition and the upstream drivers producing it.
Mucosal Inflammation and Permeability
Fecal CalprotectinMucosal inflammation marker; distinguishes structural IBD-range inflammation from functional gut disorders.
→GI-MAP Stool AnalysisComprehensive dysbiosis characterization, F. prausnitzii and SCFA producer quantification, and pathogen identification.
→ZonulinQuantifies tight junction disruption perpetuating the immune-antigen cycle driving mucosal inflammation.
→Systemic Inflammatory and Nutritional Assessment
hs-CRPSystemic inflammatory burden from intestinal inflammation and downstream LPS-driven immune activation.
→Vitamin D (25-OH)Profoundly deficient in most IBD patients; VDR signaling on intestinal epithelial cells directly regulates mucosal immune homeostasis.
→B12 and Methylmalonic AcidTerminal ileum involvement in Crohn disease impairs B12 absorption; MMA is the functional deficiency marker.
→How to Interpret These Labs Together
Fecal calprotectin above 50 mcg/g indicates mucosal inflammation warranting further evaluation. Above 150 mcg/g indicates significant mucosal inflammation that should prompt endoscopic evaluation. In established IBD, calprotectin correlates better with endoscopic findings than symptom scores or serum CRP alone and is the preferred non-invasive mucosal healing marker between colonoscopy intervals.
Vitamin D below 40 ng/mL in any IBD patient is an urgent and actionable finding. Vitamin D receptor signaling on intestinal epithelial cells is required for antimicrobial peptide production and regulatory T-cell induction. This is a direct mucosal immune regulatory mechanism correctable in virtually every patient. The target is 60 to 80 ng/mL, not 30 ng/mL as the reference range lower limit.
| Pattern | Clinical Implication |
|---|---|
| Elevated calprotectin with IBS-level symptoms and normal colonoscopy | Microscopic colitis or subclinical mucosal inflammation producing IBD-like symptoms without grossly visible mucosal disease. Requires biopsy for microscopic evaluation. Functional medicine root-cause treatment rather than standard IBS management protocols. |
| IBD in remission on biologics with persistent fatigue and extra-intestinal symptoms | Endoscopic remission does not eliminate the dysbiosis, nutritional deficiencies, and systemic inflammatory burden driving extra-intestinal symptoms. GI-MAP and comprehensive nutritional assessment are indicated regardless of remission status on standard markers. |
| F. prausnitzii severely depleted on GI-MAP in active IBD | The primary anti-inflammatory brake is absent. High-fiber prebiotic nutrition and Bifidobacterium-dominant probiotic reseeding alongside conventional management is the most mechanistically rational microbiome intervention available. |
| Elevated zonulin with active IBD symptoms | Intestinal permeability is actively perpetuating the immune-antigen contact driving mucosal inflammation. Barrier repair with L-glutamine and zinc carnosine alongside conventional management interrupts the cycle that biologic therapy alone cannot address. |
| Multiple nutritional deficiencies in IBD together | Malabsorption from active mucosal disease or post-surgical anatomy. Each deficiency should be repleted to functional sufficiency targets confirmed by repeat testing, not merely above laboratory lower reference limits. |
Common Patterns Seen in Patients
- Elevated calprotectin with IBS-level symptoms and normal colonoscopy: microscopic colitis or subclinical mucosal inflammation producing IBD-like symptoms without grossly visible mucosal disease on standard endoscopy; the calprotectin elevation is the key finding that distinguishes this pattern from functional IBS and directs toward mucosal biopsy and root-cause treatment rather than IBS management protocols
- IBD in remission on biologics with persistent fatigue and extra-intestinal symptoms: endoscopic remission does not eliminate the dysbiosis, nutritional deficiencies, and systemic inflammatory burden that drive the extra-intestinal symptoms continuing despite mucosal healing; GI-MAP and comprehensive nutritional assessment reveal the clinical picture that the biologic cannot address
- Newly diagnosed pediatric or young adult IBD with identifiable dietary triggers and microbiome imbalance: the stage at which gut microbiome restoration, dietary intervention, and nutritional optimization have the most impact on long-term disease course before chronic structural changes establish and medication burden escalates
- Refractory IBD with multiple biologic failures: identifying the gut dysbiosis pattern, dietary antigen trigger, or HPA axis-driven flare mechanism that conventional immunomodulation is not addressing changes the management approach and may restore response to medications that appeared to have failed
Treatment and Optimization Strategy
Microbiome Restoration as the Primary Functional Layer
F. prausnitzii restoration is the most important single microbiome target in inflammatory gut conditions. High-fiber anti-inflammatory nutrition with abundant prebiotic fiber from onions, garlic, leeks, asparagus, and diverse plant sources supports F. prausnitzii and Akkermansia growth. Bifidobacterium-dominant probiotic supplementation including B. longum, B. breve, and B. infantis combinations reduces intestinal inflammatory markers and supports mucosal IgA production. VSL#3, now marketed as Vivomixx, has evidence for maintenance of remission in ulcerative colitis and pouchitis. This microbiome restoration layer addresses what biologic therapy cannot: the endogenous inflammatory signaling from the dysbiotic microbiome that continues even when mucosal immune attack is suppressed.
Mucosal Healing and Barrier Repair
- Intestinal permeability repair: L-glutamine (5 to 10g daily in divided doses) is the primary fuel for intestinal epithelial cells and the most evidence-supported mucosal healing agent; zinc carnosine (75mg twice daily) provides zinc for tight junction protein synthesis and mucosal repair; colostrum provides IgG, lactoferrin, and growth factors supporting mucosal regeneration; these are complementary to biologic therapy in IBD, not alternatives to it
- Vitamin D optimization to 60 to 80 ng/mL: vitamin D3 (5,000 to 10,000 IU daily with K2 MK-7, 200mcg) with recheck at 3 months; malabsorption in Crohn disease may require higher doses to achieve the therapeutic target; vitamin D receptor signaling on intestinal epithelial cells directly regulates mucosal immune homeostasis
- Omega-3 fatty acids (3 to 4g EPA and DHA daily): shift eicosanoid balance from pro-inflammatory toward pro-resolving lipid mediators; reduce mucosal inflammatory cytokine production; omega-3 index target 8 to 12%; most IBD patients have severely depleted omega-3 status from dietary insufficiency and malabsorption
- Calprotectin-guided monitoring: repeat fecal calprotectin at each clinical interval provides the non-invasive mucosal healing assessment that correlates better with endoscopic findings than CRP or symptom scores; use as the primary objective treatment response marker between colonoscopy intervals
Nutritional Repletion and Dietary Management
- Comprehensive nutritional repletion: B12 as methylcobalamin (1,000mcg sublingual daily) for terminal ileum Crohn disease involvement; iron bisglycinate to ferritin above 70 ng/mL; zinc (25 to 30mg daily) for mucosal repair and immune function; folate as methylfolate; all repleted to functional sufficiency targets confirmed by repeat testing at 3 months
- Gluten evaluation in all IBD patients: celiac antibodies (tTG-IgA) and gluten elimination trial are appropriate for all IBD patients given the elevated prevalence of celiac disease in IBD and the zonulin-increasing effect of gliadin on intestinal permeability in susceptible individuals regardless of celiac antibody status
- Specific carbohydrate diet or IBD anti-inflammatory diet for maintenance: both diets have clinical evidence for reducing IBD disease activity scores and extending remission duration; neither is a substitute for medical management in moderate-to-severe IBD but both provide a dietary framework supporting microbiome restoration
- HPA axis support for stress-triggered flares: four-point salivary cortisol to characterize the cortisol pattern in patients who reliably flare with stress; pattern-specific HPA intervention reduces the CRH-mediated intestinal permeability increase and mast cell degranulation that translates stress physiology into mucosal immune activation
What Most Doctors Miss
- Calprotectin is not used as a routine screening tool before colonoscopy: the most cost-effective first step for distinguishing mucosal inflammation from functional gut disorders is frequently skipped in favor of direct endoscopic evaluation; fecal calprotectin before colonoscopy would eliminate unnecessary procedures and identify subclinical inflammation that colonoscopy with normal gross appearance would miss
- Nutritional deficiencies are not comprehensively assessed in IBD: B12, vitamin D, iron, zinc, and folate are reliably depleted in IBD from malabsorption and chronic inflammation; they are not routinely monitored at the frequency warranted by ongoing disease activity; repleting nutrients to functional sufficiency targets rather than laboratory lower limits is rarely applied
- Microbiome restoration is not incorporated into IBD management: biologic medications suppress the immune attack on the mucosa but do not restore the dysbiotic microbiome driving ongoing inflammatory signaling; this is the most consistently unaddressed element of IBD management in conventional practice
- Dietary antigen triggers are not investigated: food sensitivity and dietary antigen contribution to mucosal immune activation are not part of standard IBD management despite clinical evidence for dietary intervention reducing disease activity and extending remission duration
- Vitamin D is not optimized to therapeutic targets in IBD: vitamin D is occasionally monitored in IBD patients but rarely repleted to 60 to 80 ng/mL as the evidence-based target for optimal mucosal immune regulatory function; the difference between 32 ng/mL and 75 ng/mL in an IBD patient is clinically and mechanistically significant
When to Seek Medical Care
Seek immediate emergency evaluation for: severe abdominal pain with fever suggesting intestinal perforation or toxic megacolon, significant rectal bleeding producing hemodynamic instability, or rapid clinical deterioration in known IBD. These represent surgical emergencies requiring urgent evaluation. Seek urgent gastroenterology evaluation for: new onset of rectal bleeding without a prior IBD diagnosis, unexplained significant weight loss with gut symptoms, fecal calprotectin above 200 mcg/g without a current IBD diagnosis, or failure to respond to current IBD therapy within the expected timeframe.
For subclinical mucosal inflammation identified through elevated calprotectin in a patient with IBS-like symptoms, functional medicine root-cause evaluation is the appropriate next step alongside gastroenterological assessment to characterize the mucosal inflammation mechanism and exclude structural disease.
Recommended Testing
Identifying the root cause of this condition requires going beyond standard labs. The following markers provide the most clinically useful insights.
Foundational Labs
- Fecal Calprotectin
- GI-MAP Stool Analysis
- Secretory IgA
Advanced Assessment
- Zonulin
- hs-CRP
- Vitamin D
- Ferritin
- B12 / MMA
Not sure which testing applies to you?
Explore All Testing Options →Frequently Asked Questions
What is the difference between IBD and IBS?
IBD involves structural mucosal inflammation detectable on endoscopy, biopsy, and fecal calprotectin. The two main forms are Crohn disease affecting any part of the GI tract with transmural inflammation, and ulcerative colitis affecting only the colon with mucosal inflammation. IBS involves altered gut function without structural mucosal inflammation. The distinction is clinically critical because IBD requires immunomodulatory management while IBS is managed through gut motility, microbiome, and dietary approaches. Fecal calprotectin is the most reliable non-invasive test that distinguishes the two and should be ordered before attributing recurrent gut symptoms to functional IBS without investigation.
Can diet induce remission in IBD?
Dietary interventions have the strongest evidence for inducing remission in pediatric Crohn disease: exclusive enteral nutrition with a formula-based diet achieves remission rates comparable to corticosteroids in children without the growth and bone density consequences of steroid use. In adult IBD, dietary interventions including the specific carbohydrate diet and IBD anti-inflammatory diet have demonstrated reductions in disease activity scores, inflammatory markers, and medication requirements in multiple studies. Diet alone is not an adequate substitute for medical management of moderate-to-severe IBD but provides a meaningful complementary layer that supports microbiome restoration and extends remission duration.
Is stress a cause of IBD flares?
Stress does not cause IBD but is a reliable and mechanistically established flare trigger. CRH released during psychological stress acts directly on intestinal CRH receptors, increasing intestinal permeability, stimulating mast cell degranulation, and altering mucosal immune activation patterns. HPA axis assessment with four-point salivary cortisol in IBD patients who flare consistently with stress allows targeted HPA intervention alongside disease management. Psychological stress management including CBT and mindfulness-based stress reduction has demonstrated reductions in IBD flare frequency in controlled trials. The mechanism is physiological and directly actionable, not merely psychological.
What probiotics are helpful for IBD?
Evidence for specific probiotics in IBD varies by condition. VSL#3, now marketed as Vivomixx, a high-potency multi-strain probiotic, has evidence for maintenance of remission in ulcerative colitis and pouchitis after ileal pouch construction. Bifidobacterium-dominant formulations have anti-inflammatory mucosal effects and are generally beneficial for IBD microbiome support. Saccharomyces boulardii reduces the risk of antibiotic-associated dysbiosis that commonly occurs with IBD antibiotic courses. The evidence is strongest for UC and pouchitis. Crohn disease probiotic data is less consistent, likely due to the greater microbiome and location heterogeneity in Crohn disease, though Bifidobacterium-dominant formulations are generally well-tolerated and supportive of microbiome restoration goals.
How The Lamkin Clinic Approaches Inflammatory Gut Conditions
Clinical Perspective
The conversation about IBD has to expand beyond which biologic to try next. A biologic suppresses the immune attack on the mucosa. It does not fix the dysbiotic microbiome that is generating the inflammatory signaling the immune system is responding to. It does not restore F. prausnitzii, the gut's primary anti-inflammatory brake. It does not replete the vitamin D that intestinal epithelial cells need for mucosal immune regulation. It does not identify the dietary antigen that is triggering the immune response through a permeable intestinal barrier. We run the GI-MAP, we optimize vitamin D to 60 to 80 ng/mL in every IBD patient without exception, we evaluate for gluten and other dietary antigens, and we restore the microbiome toward an anti-inflammatory composition. That is the layer that determines long-term outcome when conventional management has controlled the acute inflammatory component.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
Related Conditions
Gut DysbiosisDysbiosis with F. prausnitzii depletion is the most consistent microbiome finding in inflammatory gut conditions
→Leaky GutIntestinal permeability perpetuates the immune-antigen cycle that drives and sustains mucosal inflammation
→Autoimmune ActivationIBD involves autoimmune mucosal attack with shared upstream triggers including gut permeability and antigen exposure
→Mast Cell ActivationIntestinal mast cell hyperreactivity compounds mucosal inflammation and drives visceral hypersensitivity in IBD
→Irritable Bowel SyndromeCalprotectin distinguishes IBD-range mucosal inflammation from the functional pattern of IBS
→Related Symptoms
FatigueSystemic cytokine burden and nutritional malabsorption from gut inflammation produce the disabling fatigue of IBD
→BloatingDysbiosis and altered motility from mucosal inflammation drive the gas and distension of inflammatory gut conditions
→Brain FogGut-brain axis cytokine signaling from intestinal inflammation drives cognitive symptoms that IBD patients frequently report
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Inflammatory gut conditions require evaluation of the drivers, not just management of the inflammation.
The Lamkin Clinic evaluates inflammatory gut conditions with fecal calprotectin, GI-MAP stool analysis, intestinal permeability markers, vitamin D optimization, and comprehensive nutritional assessment. Schedule a consultation for a root-cause gut inflammation evaluation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.